Profound Medical Corp Stock News

Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”).

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement previously announced on December 19, 2025 (the “Offering”) in order to accommodate participation by a long-term existing investor.

Financing included participation by healthcare-dedicated investors alongside existing shareholders Financing included participation by healthcare-dedicated investors alongside existing shareholders

TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering and a planned subsequent private placement in Canada of up to 571,428 common shares at a purchase price of $7.00 per share for aggregate gross proceeds of ...

– CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target – – CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target –

New BPH module and clinical data reinforce the TULSA Procedure™'s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption New BPH module and clinical data reinforce the TULSA Procedure™'s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption

Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy